|
Tabuľka |
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
Náklady na inovatívne lieky* |
|
|
|
|
|
|
|
|
|
|
|
|
EMA OMP |
9 876 289 |
22,7% |
|
|
|
|
|
mil. € |
|
|
|
|
|
|
|
|
|
|
|
|
VYN |
19 432 059 |
44,6% |
|
|
|
|
| Riadok v dopade |
|
|
2021 |
2022 |
2023 |
2024 |
2025 |
|
CAGR |
|
|
|
|
AVASTIN |
4 240 432 |
9,7% |
|
|
|
|
|
|
|
|
|
-20% |
-12% |
-10% |
|
|
|
|
|
|
Others |
9 975 626 |
22,9% |
|
|
|
|
|
Cena liečby 1x pacienta |
|
|
317 033,04 € |
253 626,43 € |
223 191,26 € |
200 872,13 € |
|
-14% |
|
|
|
|
|
|
|
|
|
|
|
|
Odhadovaná zľava |
|
|
0% |
30% |
40% |
40% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cena liečby 1x pacienta adj. |
|
|
317 033,04 € |
177 538,50 € |
133 914,76 € |
120 523,28 € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Počet pacientov |
|
|
12 |
44 |
75 |
100 |
|
|
|
|
|
|
In-label |
29 308 348 |
67,3% |
|
|
|
|
| 06 |
Spolu bez zlavy |
|
|
3 800,00 € |
11 200,00 € |
16 700,00 € |
20 100,00 € |
|
74% |
|
|
|
|
|
|
|
|
|
|
|
| 07 |
Dopad osobitnej úhrady lieku v ÚZS |
|
- € |
- 3 400,00 € |
- 6 700,00 € |
- 8 000,00 € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SPOLU tis. € |
|
|
3 800 € |
7 800 € |
10 000 € |
12 100 € |
|
47% |
|
|
|
|
|
|
|
|
|
|
|
|
Nárast |
|
|
|
105,3% |
28,2% |
21,0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vstupné údaje / ceny 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Novartis / Kymriah cena 2022 |
|
317 033,04 € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gilead / Yescarta |
|
304 500,00 € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gilead / Tecartus |
|
366 667,00 € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Janssen / |
|
462 000,00 € |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|